SCHEMBL22552265

SCHEMBL22552265

CC(C)c1n[nH]c(=O)c2ccc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
PRMT5 O14744 3/20 0.43
WDR77 Q9BQA1 3/20 0.43
TSHR P16473 1/20 0.40
JAK2 O60674 3/20 0.39
CHEK1 O14757 2/20 0.39
PIM1 P11309 2/20 0.39
FLT3 P36888 2/20 0.39
DYRK1A Q13627 2/20 0.39
METAP2 P50579 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17824579 0.94 PRMT5 (0.46) POLBPRMT5WDR77TSHRJAK2
SCHEMBL29480982 0.94 PRMT5 (0.46) POLBPRMT5WDR77TSHRJAK2
SCHEMBL26128332 0.89 POLB (0.43) POLBPRMT5WDR77TSHRJAK2
SCHEMBL31464970 0.89 POLB (0.43) POLBPRMT5WDR77TSHRJAK2
SCHEMBL26732624 0.84 PRMT5 (0.43) POLBPRMT5WDR77TSHRJAK2
SCHEMBL31464975 0.82 PRMT5 (0.42) POLBPRMT5WDR77TSHRJAK2
SCHEMBL29033157 0.81 PRMT5 (0.41) POLBPRMT5WDR77TSHRJAK2
SCHEMBL24076266 0.81 POLB (0.44) POLBPRMT5WDR77TSHRCHEK1
SCHEMBL30452337 0.81 POLB (0.44) POLBPRMT5WDR77TSHRCHEK1
SCHEMBL24076279 0.78 POLB (0.42) POLBPRMT5WDR77TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174278-B Dihydroorotate dehydrogenase inhibitors 詹森生物科技公司 2024-08-23 CN disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
EP-3956320-B1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-11-29 EP disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors JANSSEN BIOTECH, INC. 2023-09-12 US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115667225-A Compound (I) 詹森药业有限公司 2023-01-31 CN disclosed
US-11505536-B2 Dihydroorotate dehydrogenase inhibitors JANSSEN BIOTECH, INC. 2022-11-22 US disclosed
US-20220298137-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2022-09-22 US disclosed
CN-114174278-A Dihydroorotate dehydrogenase inhibitors 詹森生物科技公司 2022-03-11 CN disclosed
EP-3956320-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS Janssen Biotech, Inc. (US) 2022-02-23 EP disclosed
WO-2022036204-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2022-02-17 WO disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 WO disclosed
WO-2020212897-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2020-10-22 WO disclosed
US-20200331881-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B POLB 3231/4885PRMT5 3337/4885WDR77 1820/4885
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 POLB 3068/4885PRMT5 2513/4885WDR77 2935/4885
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 POLB 3737/4885PRMT5 1868/4885WDR77 1384/4885
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors DHODH, DLD, DPYD POLB 621/4885PRMT5 1788/4885WDR77 993/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 POLB 3068/4885PRMT5 2513/4885WDR77 2935/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 POLB 3068/4885PRMT5 2513/4885WDR77 2935/4885
US-11505536-B2 Dihydroorotate dehydrogenase inhibitors DHODH, DLD, DPYD POLB 621/4885PRMT5 1788/4885WDR77 993/4885
US-20220298137-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, DLD, DPYD POLB 621/4885PRMT5 1788/4885WDR77 993/4885
US-20200331881-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, DLD, DPYD POLB 621/4885PRMT5 1788/4885WDR77 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.